The results of the French Genito-Urinary Tumor Group (GETUG) P01 trial — a Phase II study of carboplatin and etoposide in men with progressive metastatic castration-resistant prostate cancer (mCRPC) — have shown that this form of combination chemotherapy has limited efficacy and an unacceptably high toxicity in men with late stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: carboplatin, castration-rsistant, etopside, mCRPC, metastasis, neuroendocine | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 